期刊
ONCOTARGET
卷 8, 期 1, 页码 228-237出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.13894
关键词
colitis; colon; inflammation; dextran sulfate sodium; CAM; FDA
资金
- National Institutes of Health Center for Colon Cancer Research, NIH [1R03CA171326]
- Core facilities in the National Institutes of Health Center for Colon Cancer Research Grant [5P20 RR-017698-08]
- NCCAM, NIH [2 P01 AT003961-06A1]
- University of South Carolina Electronic Research Administration, USCeRA [11110-15-38752]
Ulcerative colitis (UC) is a chronic lifelong inflammatory disorder of the colon, which, while untreated, has a relapsing and remitting course with increasing risk of progression toward colorectal cancer. Current medical treatment strategies of UC mostly focus on inhibition of the signs and symptoms of UC to induce remission and prevent relapse of disease activity, minimizing the impact on quality of life, but not affecting the cause of disease. To date, however, there is no single reliable treatment agent and/or strategy capable of effectively controlling colitis progression throughout the patient's life without side effects, remission, or resistance. Taking into consideration an urgent need for the new colitis treatment strategies, targets and/or modulators of inflammation, we have tested current and prospective compounds for colitis treatment and directly compared their anti-colitis potency using a dextran sulfate sodium (DSS) mouse model of colitis. We have introduced a composite score - a multi-parameters comparison tool - to assess biological potency of different compounds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据